Design Therapeutics Inc News - DSGN

Professional-Grade Tools, for Individual Investors.

FeaturedHivello Token ($HVLO) now Live

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Current Report Filing (8-k)

0001807120false00018071202022-06-152022-06-15 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...

Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference

CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a...

RBC Capital Thinks Design Therapeutics’ Stock is Going to Recover

RBC Capital analyst Leonid Timashev maintained a Buy rating on Design Therapeutics (DSGN – Research Report) on May 9 and set a price target of...

SVB Securities Thinks Design Therapeutics’ Stock is Going to Recover

In a report released today, Joseph Schwartz from SVB Securities maintained a Buy rating on Design Therapeutics (DSGN – Research Report), with a...

Notice of Effectiveness (effect)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:May 09, 2022...

Quarterly Report (10-q)

Q10001807120--12-31false0001807120us-gaap:CommonStockMember2022-01-012022-03-310001807120us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLev...

Current Report Filing (8-k)

0001807120false00018071202022-05-092022-05-09 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...

Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results

Clinical Execution of Lead GeneTAC™ Molecule, DT-216, with Initiation of Phase 1 Trial for the Treatment of...

Securities Registration Statement (simplified Form) (s-3)

As filed with the Securities and Exchange Commission on April 27, 2022 Registration No. 33...

Design Therapeutics (DSGN) Receives a Buy from Leerink Partners

In a report issued on March 30, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Design Therapeutics (DSGN – Research Report). The...

Design Therapeutics Gets Fast Track Designation for Friedreich Ataxia Treatment

By Chris Wack Design Therapeutics Inc. said the U.S. Food and Drug Administration granted fast ttack designation to DT-216 for the treatment of...

Monksdream 5 months ago

DSGN under $5

👍️0

Monksdream 9 months ago

DSGN under $5

👍️0

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Design Therapeutics Inc (DSGN)

Professional-Grade Tools, for Individual Investors.

DSGN News

FeaturedHivello Token ($HVLO) now Live

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference

RBC Capital Thinks Design Therapeutics’ Stock is Going to Recover

SVB Securities Thinks Design Therapeutics’ Stock is Going to Recover

Notice of Effectiveness (effect)

Quarterly Report (10-q)

Current Report Filing (8-k)

Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results

Securities Registration Statement (simplified Form) (s-3)

Design Therapeutics (DSGN) Receives a Buy from Leerink Partners

Design Therapeutics Gets Fast Track Designation for Friedreich Ataxia Treatment

DSGN Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Design Therapeutics Inc (DSGN) News

Design Therapeutics Inc (DSGN)

Professional-Grade Tools, for Individual Investors.

DSGN News

FeaturedHivello Token ($HVLO) now Live

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference

RBC Capital Thinks Design Therapeutics’ Stock is Going to Recover

SVB Securities Thinks Design Therapeutics’ Stock is Going to Recover

Notice of Effectiveness (effect)

Quarterly Report (10-q)

Current Report Filing (8-k)

Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results

Securities Registration Statement (simplified Form) (s-3)

Design Therapeutics (DSGN) Receives a Buy from Leerink Partners

Design Therapeutics Gets Fast Track Designation for Friedreich Ataxia Treatment

DSGN Discussion

Your Recent History

Go Ad-Free